The development of an angiogenic protein "signature" in ovarian cancer ascites as a tool for biologic and prognostic profiling


Trachana S-P, Pilalis E, Gavalas NG, Tzannis K, Papadodima O, Liontos M, Rodolakis A, Vlachos G, Thomakos N, Haidopoulos D, et al. The development of an angiogenic protein "signature" in ovarian cancer ascites as a tool for biologic and prognostic profiling. PLoS ONE [Internet]. 2016;11(6).


Advanced ovarian cancer (AOC) is one of the leading lethal gynecological cancers in developed countries. Based on the important role of angiogenesis in ovarian cancer oncogenesis and expansion, we hypothesized that the development of an "angiogenic signature" might be helpful in prediction of prognosis and efficacy of anti-angiogenic therapies in this disease. Sixty-nine samples of ascitic fluid- 35 from platinum sensitive and 34 from platinum resistant patients managed with cytoreductive surgery and 1st-line carboplatin-based chemotherapy- were analyzed using the Proteome Profiler™ Human Angiogenesis Array Kit, screening for the presence of 55 soluble angiogenesis-related factors. A protein profile based on the expression of a subset of 25 factors could accurately separate resistant from sensitive patients with a success rate of approximately 90%. The protein profile corresponding to the "sensitive" subset was associated with significantly longer PFS (8 [95% Confidence Interval {CI}: 8-9] vs. 20 months [95% CI: 15-28]; Hazard ratio {HR}: 8.3, p<0.001) and OS (20.5 months [95% CI: 13.5-30] vs. 74 months [95% CI: 36-not reached]; HR: 5.6 [95% CI: 2.8-11.2]; p<0.001). This prognostic performance was superior to that of stage, histology and residual disease after cytoreductive surgery and the levels of vascular endothelial growth factor (VEGF) in ascites. In conclusion, we developed an "angiogenic signature" for patients with AOC, which can be used, after appropriate validation, as a prognostic marker and a tool for selection for anti-angiogenic therapies. © 2016 Trachana et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Cited By :3Export Date: 18 February 2017References: Howlader, N.A., Krapcho, M., Garshell, J., Neyman, A., Altekruse, S.F., Kosary, C.L., SEER Cancer Statistics Review, 1975-2010, , http://seercancergov/csr/1975_2010/;Salani, R., Backes, F.J., Fung Kee Fung, M., Holschneider, C.H., Parker, L.P., Post treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies. Society of Gynecologic Oncologists recommendations (2011) American Journal of Obstetrics and Gynecology, 204, pp. 466-478. , PMID: 21752752; McGuire, W.P., Hoskins, W.J., Brady, M.F., Kucera, P.R., Partridge, E.E., Look, K.Y., Cyclophosphamide and Cisplatin compared with Paclitaxel and Cisplatin in patients with Stage III and Stage IV Ovarian Cancer (1996) N Engl J Med, 334, pp. 1-6. , PMID: 7494563; Obermayer, E., Castillo-Tong, D.C., Pils, D., Speiser, P., Braicu, I., Van Gorp, T., Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance: A study of the OVCAD consortium (2013) Gynecol Oncol, 128 (1), pp. 15-21. , PMID: 23017820; Taylor, D.D., Gerçel-Taylor, C., Tumour-derived exosomes and their role in cancer associated T-cell signalling defects (2005) Br J Cancer, 92 (2), pp. 305-311. , PMID: 15655551; Meirelles, K., Benedict, L.A., Dombkowski, D., Pepin, D., Preffer, F.I., Teixeira, J., Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance (2012) Proc Natl Acad Sci USA, 109 (7), pp. 2358-2363. , PMID: 22308459; Taylor, D.D., Gercel-Taylor, C., Parker, L.P., Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer (2009) Gynecol Oncol, 115 (1), pp. 112-120. , PMID: 19647308; Buckanovich, R.J., Sasaroli, D., O'Brien-Jenkins, A., Botbyl, J., Hammond, R., Katsaros, D., Tumor vascular proteins as biomarkers in ovarian cancer (2007) J Clin Oncol, 25 (7), pp. 852-861. , PMID: 17327606; Bergers, E., Benjamin, L.E., Tumorigenesis and the angiogenic switch (2003) Nat Rev Cancer, 3, pp. 401-410. , PMID: 12778130; Bamias, A., Tsiatas, M., Kafantari, E., Liakos, C., Rodolakis, A., Voulgaris, Z., Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance (2007) Gynecol Oncol, 106, pp. 75-81. , PMID: 17433425; Bamias, A., Koutsoukou, V., Terpos, E., Tsiatas, M., Liacos, C., Tsitsilonis, O., Correlation of NK-T like CD3+ CD56+ cells and CD4+ CD25+ (hi), regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first line, platinum based chemotherapy (2008) Gynecol Oncol, 108, pp. 421-427. , PMID: 18036640; Bamias, A., Pignata, S., Pujade-Lauraune, E., Angiogenesis: A promising therapeutic target for ovarian cancer (2012) Crit Rev Oncol Hematol, 84, pp. 314-326. , PMID: 22575381; Michaelis, M., Klassert, D., Barth, S., Suhan, T., Breitling, R., Mayer, B., Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells (2009) Mol Cancer, 8, p. 80. , Sep 29; PMID: 19788758; Biroccio, A., Candiloro, A., Mottolese, M., Sapora, O., Albini, A., Zupi, G., Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line (2000) FASEB J, 5, pp. 652-660; Anai, S., Goodison, S., Shiverick, K., Hirao, Y., Brown, B.D., Rosser, C.J., Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts (2007) Mol. Cancer Ther., 1, pp. 101-111; Tu, S.P., Cui, J.T., Liston, P., Huajiang, X., Xu, R., Lin, M.C., Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant (2005) Gastroenterology, 2, pp. 361-375; Rustin, G.J., Vergote, I., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA125 agreed by the Gynecological Cancer Intergroup (GCIG) (2011) Int J Gynecological Cancer, 21 (2), pp. 419-423; Korampalli, T.S., Green, V.L., Greenman, J., Stafford, N.D., Protein profiling of angiogenesis-related growth factors in laryngeal carcinoma: Pattern of protein expression in relation to tumour progression (2011) Int J Oncol, 39, pp. 1033-1039. , PMID: 21743965; Su, Y., Murali, T.M., Pavlovic, V., Schaffer, M., Kasif, S., RankGene: Identification of diagnostic genes based on expression data (2003) Bioinformatics, 19, pp. 1578-1579. , PMID: 12912841; Kent, J., Information gain and a general measure of correlation (1983) Biometrika, 70, pp. 163-173; Ransohoff, D.F., Rules of evidence for cancer molecular-marker discovery and validation (2004) Nat Rev Cancer, 4 (4), pp. 309-314. , PMID: 15057290; Davidson, B., Espina, V., Steinberg, S.M., Flørenes, V.A., Liotta, L.A., Kristensen, G.B., Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling (2006) Clin Cancer Res, 12 (3), pp. 791-799. , PMID: 16467090; Peterson, V.M., Castro, C.M., Chung, J., Miller, N.C., Ullal, A.V., Castano, M.D., Ascites analysis by a microfluidic chip allows tumor-cell profiling (2013) PNAS, ,; Gourley, C., McCavigan, A., Perren, T., Paul, J., Michie, C.O., Churchman, M., Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab (2014) J Clin Oncol, 32, p. 5502; Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin (1991) J Clin Oncol, 9, pp. 389-393. , PMID: 1999708; Sallinen, H., Heikura, T., Koponen, J., Kosma, V.M., Heinonen, S., Ylä-Herttuala, S., Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer (2014) BMC Cancer, 14, p. 696. , PMID: 25245329; Secord, A.A., Nixon, A.B., Hurwitz, H.I., The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer (2014) Gynecol Oncol, 135, pp. 349-358. , PMID: 25178997; Cheng, C., Bin, B., Li, Y., Serum Vascular Endothelial Growth Factor (VEGF-C) as a Diagnostic and Prognostic Marker in Patients with Ovarian Cancer (2013) PLoS One, 8 (2). , PMID: 23383322; Chen, Y., Zhang, L., Pan, Y., Ren, X., Hao, Q., Over-Expression of Semaphorin4D, Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor Is Related to Poor Prognosis in Ovarian Epithelial Cancer (2012) Int J Mol Sci, 13, pp. 13264-13274. , PMID: 23202951; Lose, F., Nagle, C.M., O'Mara, T., Batra, J., Bolton, K.L., Song, H., Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival (2010) Gynecol Oncol, 119, pp. 479-483. , PMID: 20832104; Bamberger, E.S., Perrett, C.W., Angiogenesis in ephithelian ovarian cancer (2002) J Clin Pathol: Mol Pathol, 55, pp. 348-359; Watanabe, Y., Nakai, H., Ueda, H., Nazaki, K., Hoshiai, H., Nada, K., Platelet-derived endothelial cell growth factors predicts of progression and recurrence in primary epithelial ovarian cancer (2003) Cancer Lett, 200 (2), pp. 173-176. , PMID: 14568172; Morimoto, Y., Hasegawa, K., Sawai, T., Kishimoto, Y., Akimoto, T., Significance of tissue thymidine phosphorylase and dihydropyrimidine dehydrogenase activities in ovarian cancer (2004) Gan To Kagaku Ryoho, 31 (13), pp. 2195-2198. , PMID: 15628771; Matei, D., Kelich, S., Cao, L., Menning, N., Emerson, R., Rao, J., PDGF BB induces VEGF secretion in ovarian cancer (2007) Cancer Biology and Therapy, 6 (12), pp. 1951-1959. , PMID: 18075302; Hata, K., Osaki, M., Dhar, D.K., Nakayama, K., Fujiwaki, R., Ito, H., Evaluation of the angiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line (2004) Cancer Chemother. Pharmacol., 53 (1), pp. 68-74. , PMID: 14569416; Monk, B.J., Poveda, A., Vergote, I., Raspagliesi, F., Fujiwara, K., Bae, D.S., Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial (2014) Lancet Oncol, 15 (8), pp. 799-808. , PMID: 24950985; Rosano, L., Cianfrocca, R., Spinella, F., Di Castro, V., Nicotra, M.R., Lucidi, A., Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells (2011) Clin Cancer Res, 17 (8), pp. 2350-2360. , PMID: 21220476; Del Bufalo, D., Di Castro, V., Biroccio, A., Varmi, M., Salani, D., Rosano, L., Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: Requirement for AKT activation (2002) Mol Pharmacol, 61 (3), pp. 524-532. , PMID: 11854432; Miyamoto, S., Iwamoto, R., Furuya, A., Takahashi, K., Sasaki, Y., Ando, H., A novel Anti-Human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells (2011) Clin Cancer Res, 10, pp. 1058-1078; Gan, Y., Wientjes, M.G., Au, J.L., Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors (2006) Pharm Res, 6, pp. 1324-1331; Tanaka, Y., Miyamoto, S., Suzuki, S.O., Oki, E., Yagi, H., Sonoda, K., Clinical significance of heparin-binding epidermal growth factor- like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer (2005) Clin Cancer Res, 11 (13), pp. 4783-4792. , PMID: 16000575; Eckstein, N., Servan, K., Girard, L., Cai, D., Von Jonquieres, G., Jaehde, U., Epidermal Growth Factor Receptor pathway analysis identifies Amphiregulin as a key factor for Cisplatin resistance of human breast cancer cells (2008) J Biol Chem, 283 (2), pp. 739-750. , PMID: 17942395; Tran, E., Nielsen, J.S., Wick, D.A., Ng, A.V., Johnson, L.D., Nesslinger, N.J., Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines (2010) Plos One, 5 (12). , PMID: 21203522; Ray, K.C., Blaine, S.A., Washington, M.K., Braun, A.H., Singh, A.B., Harris, R.C., Transmembrane and soluble isoforms of heparin-binding epidermal growth factor-like growth factor regulate distinct processes in the pancreas (2009) Gastroenterology, 137 (5), pp. 1785-1794. , Nov; PMID: 19689925; Kim, W., Kim, K.S., Lee, J.E., Noh, D.Y., Kim, S.W., Jung, Y.S., Development of Novel Breast Cancer Recurrence Prediction Model Using Support Vector Machine (2012) J Breast Cancer, 15, pp. 230-238. , PMID: 22807942; Cortes, C., Vapnik, V., Support-vector networks (1995) Mach Learn, 20, pp. 273-297; Kerbel, R.S., Kamen, B.A., The anti-angiogenic basis of metronomic chemotherapy (2004) Nat Rev Cancer, 4, p. 423. , PMID: 15170445; Yang, H., Chen, B., CD147 in Ovarian and Other Cancers (2013) Int J Gynecol Cancer, 23, pp. 2-8. , PMID: 23221648; Lloyd, K.L., Cree, I.A., Savage, R.S., Prediction of resistance to chemotherapy in ovarian cancer: A systematic review (2015) BMC Cancer, 15, p. 117. , PMID: 25886033; Niero, E.L., Rocha-Sales, B., Lauand, C., Cortez, B.A., De Souza, M.M., Rezende-Teixeira, P., The multiple facets of drug resistance: One history, different approaches (2014) Journal of Experimental & Clinical Cancer Research, 33, p. 37; Bonneau, C., Rouzier, R., Geyl, C., Cortez, A., Castela, M., Lis, R., Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma (2015) Gynecol Oncol, 136 (1), pp. 112-120. , PMID: 25449309